Zoledronat Actavis Onko (sometimes called zoledronate) is in a group of medicines called bisphosphonates (bis FOS fo nayts). Zoledronat Actavis Onko inhibits the release of calcium from bones.
Zoledronat Actavis Onko and Zoledronat Actavis Onko are two different brands of Zoledronat Actavis Onko.
The Zoledronat Actavis Onko brand of Zoledronat Actavis Onko is used to treat Paget's disease, and to treat or prevent osteoporosis in postmenopausal women or people who take certain steroid medicines. Zoledronat Actavis Onko is also used to increase bone mass in men with osteoporosis.
The Zoledronat Actavis Onko brand of Zoledronat Actavis Onko is used to treat high blood levels of calcium caused by cancer (hypercalcemia of malignancy). Zoledronat Actavis Onko also treats multiple myeloma (a type of bone marrow cancer) or bone cancer that has spread from elsewhere in the body.
You should not be treated with Zoledronat Actavis Onko if you are already receiving Zoledronat Actavis Onko.
Zoledronat Actavis Onko may also be used for purposes not listed in this medication guide.
Zoledronat Actavis Onko indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
Treatment of Osteoporosis in Postmenopausal Women
Zoledronat Actavis Onko is indicated for treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, diagnosed by bone mineral density (BMD) or prevalent vertebral fracture, Zoledronat Actavis Onko reduces the incidence of fractures (hip, vertebral and non-vertebral osteoporosis-related fractures). In patients at high risk of fracture, defined as a recent low-trauma hip fracture, Zoledronat Actavis Onko reduces the incidence of new clinical fractures.
Prevention of Osteoporosis in Postmenopausal Women
Zoledronat Actavis Onko is indicated for prevention of osteoporosis in postmenopausal women.
Osteoporosis in Men
Zoledronat Actavis Onko is indicated for treatment to increase bone mass in men with osteoporosis.
Zoledronat Actavis Onko is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months.
Paget's Disease of Bone
Zoledronat Actavis Onko is indicated for treatment of Paget's disease of bone in men and women. Treatment is indicated in patients with Paget’s disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease.
Important Limitations of Use
The safety and effectiveness of Zoledronat Actavis Onko for the treatment of osteoporosis is based on clinical data of three years duration. The optimal duration of use has not been determined. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.
How should I use Zoledronat Actavis Onko?
Use Zoledronat Actavis Onko as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Zoledronat Actavis Onko comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Zoledronat Actavis Onko refilled.
Zoledronat Actavis Onko is usually given as an injection at your doctor's office, hospital, or clinic.
Drink at least 2 full glasses (16 oz/480 mL) of fluid (eg, water) within a few hours before you receive Zoledronat Actavis Onko, as directed by your doctor.
Do not use Zoledronat Actavis Onko if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.
If you miss a dose of Zoledronat Actavis Onko, contact your doctor right away.
Ask your health care provider any questions you may have about how to use Zoledronat Actavis Onko.
Uses of Zoledronat Actavis Onko in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
Use: Labeled Indications
Bone metastases from solid tumors:Zoledronat Actavis Onko: Treatment of documented bone metastases from solid tumors (in conjunction with standard antineoplastic therapy); prostate cancer should have progressed following treatment with at least one hormonal therapy.
Hypercalcemia of malignancy:Zoledronat Actavis Onko: Treatment of hypercalcemia (albumin-corrected serum calcium ≥12 mg/dL) of malignancy.
Limitations of use: Safety and efficacy for treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions have not been established.
Multiple myeloma:Zoledronat Actavis Onko: Treatment of osteolytic lesions of multiple myeloma.
Osteoporosis:Zoledronat Actavis Onko, Zoledronat Actavis Onko [Canadian product]: Treatment and prevention of osteoporosis in postmenopausal females; treatment to increase bone mass in males with osteoporosis; treatment and prevention of glucocorticoid-induced osteoporosis in males and females who are initiating or continuing systemic glucocorticoids with a prednisone dosage of ≥7.5 mg/day (or equivalent) and who are expected to remain on glucocorticoids for at least 12 months.
Paget disease:Zoledronat Actavis Onko, Zoledronat Actavis Onko [Canadian product]: Treatment of Paget disease of bone in males and females. Note: Zoledronat Actavis Onko is considered the most efficacious bisphosphonate with respect to treating bone pain as well as suppressing metabolic bone activity. In patients without contraindications, Endocrine Society guidelines as well as some international guidelines recommend Zoledronat Actavis Onko as the treatment of choice (Endocrine Society [Singer 2014]; Ralston 2019).
Off Label Uses
Breast cancer, early (adjuvant therapy)
A systematic review which included studies in women with early breast cancer demonstrated an advantage (reduced risk of bone metastases) with the adjuvant use of bisphosphonate therapy (including Zoledronat Actavis Onko) in postmenopausal females.
Zoledronat Actavis Onko description
Each vial contains Zoledronic Acid monohydrate equivalent to Zoledronat Actavis Onko 4 mg.
Zoledronat Actavis Onko belongs to the chemotherapy drug class of bisphosphonates. It is an inhibitor of osteoclastic bone resorption and is designated chemically as (1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate. It is highly soluble in 0.1N sodium hydroxide solution, sparingly soluble in water and 0.1N hydrochloric acid and practically insoluble in organic solvents. 0.7% solution of Zoledronat Actavis Onko in water has a pH approximately 2.0. The molecular formula and molecular weight of Zoledronat Actavis Onko is C5H10N2O7P2•H2O and 290.1 g/mol, respectively.
Zoledronat Actavis Onko dosage
General: The incidence of post-dose symptoms occurring within the first 3 days after administration of Zoledronat Actavis Onko can be reduced with the administration of paracetamol or ibuprofen shortly following Zoledronat Actavis Onko administration.
Patients must be appropriately hydrated prior to administration of Zoledronat Actavis Onko. This is especially important in the elderly and for patients receiving diuretic therapy.
Treatment of Postmenopausal Osteoporosis: Recommended Dose: Single IV infusion of Zoledronat Actavis Onko 5 mg administered once a year.
Adequate supplemental calcium and vitamin D intake is important in women with osteoporosis if dietary intake is inadequate.
Prevention of Clinical Fractures after a Hip Fracture: Recommended Dose: Single IV infusion of Zoledronat Actavis Onko 5 mg administered once a year.
Supplemental calcium and vitamin D intake is recommended for patients treated to prevent clinical fractures after a low-trauma hip fracture.
Treatment of Osteoporosis in Men: Recommended Dose: Single IV infusion of Zoledronat Actavis Onko 5 mg administered once a year.
Adequate supplemental calcium and vitamin D intake is important in men with osteoporosis if dietary intake is inadequate.
Treatment and Prevention of Glucocorticoid-Induced Osteoporosis: Recommended Dose: Single IV infusion of Zoledronat Actavis Onko 5 mg administered once a year.
Adequate supplemental calcium and vitamin D intake is important in patients with osteoporosis if dietary intake is inadequate.
Prevention of Postmenopausal Osteoporosis: Recommended Regimen: Single IV infusion of Zoledronat Actavis Onko 5 mg. An annual assessment of the patient's risk of fracture and clinical response to treatment should guide the decision of when re-treatment should occur.
For the prevention of postmenopausal osteoporosis it is important that patients be adequately supplemented with calcium and vitamin D if dietary intake is inadequate.
Treatment of Paget's Disease of Bone: Zoledronat Actavis Onko should be prescribed only by physicians with experience in treatment of Paget's disease of the bone. The recommended dose is a single IV infusion of Zoledronat Actavis Onko 5 mg. Re-Treatment of Paget's Disease: Specific re-treatment data are not available. After a single treatment with Zoledronat Actavis Onko in Paget's disease, an extended remission period is observed in responding patients. However, re-treatment with Zoledronat Actavis Onko may be considered in patients who have relapsed, based on increases in serum alkaline phosphatase, in patients who failed to achieve normalization of serum alkaline phosphatase or in patients with symptoms, as dictated by medical practice 12 months after the initial dose.
In patients with Paget's disease, adequate vitamin D intake is recommended in association with Zoledronat Actavis Onko administration. In addition, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured in patients with Paget's disease for at least 10 days following Zoledronat Actavis Onko administration.
Special Populations: Patients with Renal Impairment: The use of Zoledronat Actavis Onko in patients with CrCl <35 mL/min is not recommended due to limited clinical safety data in such patients.
No dose adjustment is necessary in patients with CrCl ≥35 mL/min.
Patients with Hepatic Impairment: No dose adjustment is required.
Elderly (≥65 years): No dose adjustment is necessary since bioavailability, distribution and elimination were similar in elderly patients and younger subjects.
Administration: Zoledronat Actavis Onko (5 mg in 100 mL ready-to-infuse solution) is administered IV via a vented infusion line, given at a constant infusion rate. The infusion must not be <15 min.
For information on the infusion of Zoledronat Actavis Onko, see Instructions for Use & Handling under Cautions for Usage.
No in vivo drug interaction studies have been performed for Zoledronat Actavis Onko. In vitro and ex vivo studies showed low affinity of Zoledronat Actavis Onko for the cellular components of human blood. In vitro mean Zoledronat Actavis Onko protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL. In vivo studies showed that Zoledronat Actavis Onko is not metabolized, and is excreted into the urine as the intact drug.
Caution is advised when bisphosphonates, including Zoledronat Actavis Onko, are administered with aminoglycosides, since these agents may have an additive effect to lower serum calcium level for prolonged periods. This effect has not been reported in Zoledronat Actavis Onko clinical trials.
Caution should also be exercised when Zoledronat Actavis Onko is used in combination with loop diuretics due to an increased risk of hypocalcemia.
Caution is indicated when Zoledronat Actavis Onko is used with other potentially nephrotoxic drugs such as nonsteroidal anti-inflammatory drugs.
Drugs Primarily Excreted By The Kidney
Renal impairment has been observed following the administration of Zoledronat Actavis Onko in patients with pre-existing renal compromise or other risk factors. In patients with renal impairment, the exposure to concomitant medications that are primarily renally excreted (e.g., digoxin) may increase. Consider monitoring serum creatinine in patients at risk for renal impairment who are taking concomitant medications that are primarily excreted by the kidney.
Postmenopausal Osteoporosis: In HORIZON-PFT, the Phase III randomized, double-blind, placebo-controlled, multinational study of 7736 women aged 65-89 years, there were no significant differences in the overall incidence of serious adverse events compared to placebo and most adverse events were mild to moderate. Zoledronat Actavis Onko was administered once yearly for 3 consecutive years for a total of 3 doses.
Consistent with the IV administration of bisphosphonates, Zoledronat Actavis Onko has been most commonly associated with the following post-dose symptoms: Fever (18.1%), myalgia (9.4%), flu-like symptoms (7.8%), arthralgia (6.8%) and headache (6.5%), the majority of which occur within the first 3 days following Zoledronat Actavis Onko administration. The majority of these symptoms were mild to moderate in nature and resolved within 3 days of the event onset. The incidence of these symptoms decreased markedly with subsequent doses of Zoledronat Actavis Onko.
The incidence of post-dose symptoms occurring within the first 3 days after administration of Zoledronat Actavis Onko, can be reduced by approximately 50% with the administration of paracetamol or ibuprofen shortly following Zoledronat Actavis Onko administration.
Very common (≥1/10), common (≥1/100, <1/10), uncommon (>1/1000, <1/100), rare (>1/1000, <1/10,000) adverse reactions suspected (investigator assessment) to be associated with Zoledronat Actavis Onko are shown as follows: Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Adverse drug reactions suspected* (at least 1%) to be associated with Zoledronat Actavis Onko in postmenopausal osteoporosis in HORIZON-PFT study:
Skin and Subcutaneous Tissue Disorders: Uncommon: Rash.
Musculoskeletal Disorders: Common: Myalgia, arthralgia, bone pain, back pain, pain in extremity. Uncommon: Joint swelling.
Renal and Urinary Disorders: Uncommon: Increase blood creatinine.
General Disorders and Administration Site Conditions: Very common: Fever. Common: Hypocalcemiaa, flu-like symptomsc, chills, fatigue, asthenia, pain, malaise, rigorsa. Uncommon: Anorexia, peripheral edema, thirst.
*Incidence based on investigator assessment of causality and includes those events with a greater frequency than placebo.
Key deviations in the adverse events in the Paget's disease clinical trials compared to the postmenopausal HORIZON-PFT trial are summarized as follows:
a Common in Paget's disease only.
b Common in Paget's disease.
c Very common in Paget's disease.
In one 3-year trial in postmenopausal osteoporosis women (HORIZON-PFT), the overall incidence of atrial fibrillation was low, reported in 2.5% of patients (96 out of 3862) in the Zoledronat Actavis Onko group versus 1.9% of patients (75 out of 3852) in the placebo group. The increased incidence observed in this trial has not been observed in other clinical trials with Zoledronat Actavis Onko.
Class Effects: Renal Dysfunction: Treatment with IV bisphosphonates, including Zoledronat Actavis Onko, has been associated with renal dysfunction manifested as deterioration in renal function (ie, increased serum creatinine) and in rare cases, acute renal failure. Renal dysfunction has been observed following the administration of Zoledronat Actavis Onko, especially in patients with preexisting renal compromise or additional risk factors (eg, oncology patients with chemotherapy, concomitant nephrotoxic medications, severe dehydration), the majority of whom received a 4-mg dose every 3-4 weeks, but it has been observed in patients after a single administration.
In the HORIZON-PFT trial, the change in creatinine clearance (measured annually prior to dosing), and the incidence of renal failure and impairment was comparable for both the Zoledronat Actavis Onko and placebo treatment groups over 3 years. There was a transient increase in serum creatinine observed within 10 days in 1.8% of Zoledronat Actavis Onko-treated patients versus 0.8% of placebo-treated patients.
Laboratory Findings: In the HORIZON-PFT trial, approximately 0.2% of patients had notable declines of serum calcium levels (<1.87 mmol/L) following Zoledronat Actavis Onko administration. No symptomatic cases of hypocalcemia were observed.
In the Paget's disease trials, symptomatic hypocalcemia was observed in approximately 1% of patients, all of which resolved.
Local Reactions: Local reactions at the infusion site eg, redness, swelling and/or pain were reported (0.7%) following the administration of Zoledronat Actavis Onko.
Osteonecrosis of the Jaw: Cases of osteonecrosis (primarily of the jaw) have been reported predominantly in cancer patients treated with bisphosphonates, including Zoledronat Actavis Onko (uncommon). Many of these patients had signs of local infection including osteomyelitis, and the majority of the reports refer to cancer patients following tooth extractions or other dental surgeries. Osteonecrosis of the jaw has multiple well documented risk factors including a diagnosis of cancer, concomitant therapies (eg, chemotherapy, radiotherapy, corticosteroids) and co-morbid conditions (eg, anemia, coagulopathies, infection, preexisting dental disease). Although causality has not been determined, it is prudent to avoid dental surgery as recovery may be prolonged. In the HORIZON-PFT trial in 7736 patients, ONJ has been reported in 1 patient treated with Zoledronat Actavis Onko and 2 patients treated with placebo. All 3 cases resolved.
Zoledronat Actavis Onko can harm your kidneys. This effect is increased when you also use other medicines harmful to the kidneys, such as: chemotherapy, antiviral medication, pain or arthritis medicine, injected antibiotics, or medicines to treat a bowel disorder or prevent organ transplant rejection. You may need dose adjustments or special tests if you use any of these medications.
Do not receive Zoledronat Actavis Onko without telling your doctor if you have had an allergic reaction to Zoledronat Actavis Onko or similar medicine such as alendronate (Fosamax), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel), or tiludronate (Skelid).
Do not use Zoledronat Actavis Onko if you are pregnant. It could harm the unborn baby.
Your doctor may recommend you have a dental exam for preventive tooth and gum care before you start your treatment with Zoledronat Actavis Onko. This is especially important if you have cancer, if you are undergoing chemotherapy or using steroids, or if you have poor dental health.
Some people using medicines similar to Zoledronat Actavis Onko have developed bone loss in the jaw, also called osteonecrosis of the jaw. Symptoms of this condition may include jaw pain, swelling, numbness, loose teeth, gum infection, or slow healing after injury or surgery involving the gums. You may be more likely to develop osteonecrosis of the jaw if you have cancer or have been treated with chemotherapy, radiation, or steroids. Other conditions associated with osteonecrosis of the jaw include blood clotting disorders, anemia (low red blood cells), and pre-existing dental problems.
Avoid having any type of dental surgery while you are being treated with Zoledronat Actavis Onko. It may take longer than normal for you to recover.
Active ingredient matches for Zoledronat Actavis Onko:
DailyMed. "ZOLEDRONIC ACID: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Zoledronat Actavis Onko are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Zoledronat Actavis Onko. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
Consumer reported age
No survey data has been collected yet
There are no reviews yet. Be the first to write one!